Jennifer Taubert - Johnson Johnson Chairman

JNJ Stock  EUR 142.26  0.26  0.18%   

Chairman

Ms. Jennifer L Taubert is the Executive Vice President Worldwide Chairman, Pharmaceuticals of the Company. She has joined the Company in 2005 as Worldwide Vice President at Johnson Johnson Pharmaceutical Services, a subsidiary of the Company. She held several executive positions in the Pharmaceutical sector until 2012 when she was appointed Company Group Chairman, North America Pharmaceuticals, and in 2015 became Company Group Chairman, The Americas, Pharmaceuticals. In July 2018, Ms. Taubert was promoted to Executive Vice President, Worldwide Chairman, Pharmaceuticals, and became a member of the Executive Committee. since 2018.
Age 59
Tenure 6 years
Phone732 524 0400
Webhttps://www.jnj.com

Johnson Johnson Management Efficiency

The company has return on total asset (ROA) of 0.0871 % which means that it generated a profit of $0.0871 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2379 %, meaning that it generated $0.2379 on every $100 dollars invested by stockholders. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities.
Johnson Johnson has accumulated 26.89 B in total debt with debt to equity ratio (D/E) of 0.48, which is about average as compared to similar companies. Johnson Johnson has a current ratio of 1.36, which is within standard range for the sector. Debt can assist Johnson Johnson until it has trouble settling it off, either with new capital or with free cash flow. So, Johnson Johnson's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Johnson Johnson sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Johnson to invest in growth at high rates of return. When we think about Johnson Johnson's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 4 records

CHAIRMAN Age

Heinz SchimmelbuschAmgen Inc
75
Steve HankeAmgen Inc
77
Willem HasselAmgen Inc
73
Robert JDMerck Co
56
Johnson Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. Johnson Johnson was founded in 1886 and is based in New Brunswick, New Jersey. JOHNSON JOHNSON operates under Drug ManufacturersGeneral classification in Germany and is traded on Frankfurt Stock Exchange. It employs 136000 people. Johnson Johnson (JNJ) is traded on Frankfurt Exchange in Germany and employs 152,700 people.

Management Performance

Johnson Johnson Leadership Team

Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
Dirk Brinckman, Chief Officer
Robert Decker, Controller Officer
Alex Gorsky, Chairman of the Board, CEO
Jessica Moore, VP Relations
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals
Joseph CPA, Ex CFO
James Swanson, Ex Officer
Elizabeth Forminard, Exec Counsel
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals
Peter Fasolo, Vice President - Global Human Resources

Johnson Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in Johnson Stock

When determining whether Johnson Johnson is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Johnson Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Johnson Johnson Stock. Highlighted below are key reports to facilitate an investment decision about Johnson Johnson Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more detail on how to invest in Johnson Stock please use our How to Invest in Johnson Johnson guide.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Please note, there is a significant difference between Johnson Johnson's value and its price as these two are different measures arrived at by different means. Investors typically determine if Johnson Johnson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Johnson Johnson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.